Shun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shun He has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Baodong Ye
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
1 shared publication - Dijiong Wu
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, P.R. China
1 shared publication - Jingjing Liu
School of Life Science and Technology, The Key Laboratory of Developmental Genes and Human Disease, Southeast University
1 shared publication - Kunpeng Zhang
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China, zjhtcm.com
1 shared publication - Qi Liu
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
1 shared publication - Xinru Jia
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
1 shared publication
Latest Publications
- Open Access
- 31 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e5577070
Myeloid‐Derived Suppressor Cells: Immunoregulatory Roles and Therapeutic Prospects in Immune‐Mediated Hematological Disorders
Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that have been increasingly defined and characterized over the past two decades, known for their remarkable capacity to expand and exert immunosuppressive effects in various pathological contexts, such as malignancies, infections, and inflammatory diseases. Although MDSCs have attracted significant attention in tumor immunology, their multifaceted roles in immune‐mediated hematological disorders remain comparatively understudied and less understood, especially in contrast to their well‐documented functions in both solid and hematological malignancies. This review delves into the biological characteristics and functional mechanisms of MDSCs, as well as their dual immunomodulatory roles in various immune‐mediated hematological disorders such as immune thrombocytopenia and aplastic anemia. Substantial evidence indicates that in these diseases, the expansion, recruitment, and function of MDSCs are significantly altered, with their levels closely correlated to disease activity. Based on these findings, we further explore the therapeutic potential of targeting MDSCs. Manipulating MDSCs offers a pioneering perspective for the development of next‐generation immunotherapies, which holds promise for reshaping the current treatment landscape of immune‐mediated hematological disorders.
- 31 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e5577070
Open AccessMyeloid‐Derived Suppressor Cells: Immunoregulatory Roles and Therapeutic Prospects in Immune‐Mediated Hematological Disorders
Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that have been increasingly defined and characterized over the past two decades, known for their remarkable capacity to expand and exert immunosuppressive effects in various pathological contexts, such as malignancies, infections, and inflammatory diseases. Although MDSCs have attracted significant attention in tumor immunology, their multifaceted roles in immune‐mediated hematological disorders remain comparatively understudied and less understood, especially in contrast to their well‐documented functions in both solid and hematological malignancies. This review delves into the biological characteristics and functional mechanisms of MDSCs, as well as their dual immunomodulatory roles in various immune‐mediated hematological disorders such as immune thrombocytopenia and aplastic anemia. Substantial evidence indicates that in these diseases, the expansion, recruitment, and function of MDSCs are significantly altered, with their levels closely correlated to disease activity. Based on these findings, we further explore the therapeutic potential of targeting MDSCs. Manipulating MDSCs offers a pioneering perspective for the development of next‐generation immunotherapies, which holds promise for reshaping the current treatment landscape of immune‐mediated hematological disorders.